Skip to main content
logo
Biodyne Co., Ltd. (KOSDAQ:314930)
South Korea flag South Korea · Delayed Price · Currency is KRW
8,530.00
+30.00 (0.35%)
At close: Aug 11, 2026

Biodyne Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024
Period EndingMar '26 Dec '25 Dec '24
Revenue
6,9787,0285,271
Revenue Growth
-33.32%-
Gross Profit
4,4974,4682,438
Operating Income
1,057652.26-1,730
Net Income
1,442851.5910.77
Earnings Per Share
48.7228.89-
EPS Growth
---

Revenue by Segment
Fiscal YearFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec '24 Dec '23 Dec '22 Dec '21 Dec '20
Liquid Based Cytology Diagnostic Reagent Kit - Solution Etc.
4,2533,3503,5352,6572,977
Liquid Based Cytology Equipment
771643545639625
Liquid Based Cytology Equipment - Others
231704487242
Liquid Based Cytology Diagnostic Reagent Kit - Others
16262339527

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024
Period EndingMar '26 Dec '25 Dec '24
Cash & Investments
15,22315,98120,713
Total Debt
8.6711.0412.07
Net Cash (Debt)
15,21415,97020,701
Net Cash Growth
--22.86%-
Net Cash Per Share
514.03541.77-

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024
Period EndingMar '26 Dec '25 Dec '24
Operating Cash Flow
12.18830.26877.41
Capital Expenditures
-3,311-3,431-539.15
Free Cash Flow
-3,299-2,601338.26
Free Cash Flow Growth
---

Margins
Chart
Fiscal YearTTMFY 2025FY 2024
Period EndingMar '26 Dec '25 Dec '24
Gross Margin
64.44%63.57%46.25%
Operating Margin
15.14%9.28%-32.81%
Pretax Margin
21.85%11.83%-2.68%
Profit Margin
20.66%12.12%0.20%
FCF Margin
-47.28%-37.01%6.42%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024
Period EndingAug '26 Dec '25 Dec '24
PE Ratio
175.10471.8444493.04
Forward PE
57.54110.44175.00
P/FCF Ratio
--1416.66
PS Ratio
36.0357.1890.91